Eli Lilly’s October 2024 material transfer and platform evaluation agreement with Peptron covers feasibility testing of the SmartDepot microsphere sustained-release technology on unspecified peptide candidates, with the review window explicitly extended in late 2025 through October 7, 2026. Recent July 2026 company statements confirmed the work remains active across multiple assets but excludes high-profile candidates such as tirzepatide, while Lilly separately partnered with Camurus for comparable long-acting delivery. With only weeks remaining before the deadline and no disclosed positive evaluation data or term-sheet progress, traders view a completed licensing deal as improbable. The market-implied 84.5% probability of “No” therefore reflects the ongoing, non-binding evaluation stage and typical timelines for moving from feasibility results to a definitive agreement.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
16% chance
$11,264 Vol.
$11,264 Vol.
6 out 2026
16% chance
$11,264 Vol.
$11,264 Vol.
6 out 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 material transfer and platform evaluation agreement with Peptron covers feasibility testing of the SmartDepot microsphere sustained-release technology on unspecified peptide candidates, with the review window explicitly extended in late 2025 through October 7, 2026. Recent July 2026 company statements confirmed the work remains active across multiple assets but excludes high-profile candidates such as tirzepatide, while Lilly separately partnered with Camurus for comparable long-acting delivery. With only weeks remaining before the deadline and no disclosed positive evaluation data or term-sheet progress, traders view a completed licensing deal as improbable. The market-implied 84.5% probability of “No” therefore reflects the ongoing, non-binding evaluation stage and typical timelines for moving from feasibility results to a definitive agreement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado Aberto: May 5, 2026, 8:02 PM ET
Volume
$11,264Data de Término
7 out 2026Mercado Aberto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 material transfer and platform evaluation agreement with Peptron covers feasibility testing of the SmartDepot microsphere sustained-release technology on unspecified peptide candidates, with the review window explicitly extended in late 2025 through October 7, 2026. Recent July 2026 company statements confirmed the work remains active across multiple assets but excludes high-profile candidates such as tirzepatide, while Lilly separately partnered with Camurus for comparable long-acting delivery. With only weeks remaining before the deadline and no disclosed positive evaluation data or term-sheet progress, traders view a completed licensing deal as improbable. The market-implied 84.5% probability of “No” therefore reflects the ongoing, non-binding evaluation stage and typical timelines for moving from feasibility results to a definitive agreement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264Data de Término
7 out 2026Mercado Aberto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 material transfer and platform evaluation agreement with Peptron covers feasibility testing of the SmartDepot microsphere sustained-release technology on unspecified peptide candidates, with the review window explicitly extended in late 2025 through October 7, 2026. Recent July 2026 company statements confirmed the work remains active across multiple assets but excludes high-profile candidates such as tirzepatide, while Lilly separately partnered with Camurus for comparable long-acting delivery. With only weeks remaining before the deadline and no disclosed positive evaluation data or term-sheet progress, traders view a completed licensing deal as improbable. The market-implied 84.5% probability of “No” therefore reflects the ongoing, non-binding evaluation stage and typical timelines for moving from feasibility results to a definitive agreement.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions